The FDA has approved the injection of Risperdal Consta (risperidone long-acting injection, from Janssen) into the deltoid muscle of the arm for the treatment of schizophrenia. This approval was based ...

The first under-the-skin, long-acting risperidone injection offers a new maintenance option for adults with bipolar 1 ...

TITUSVILLE, N.J., Oct. 9 /PRNewswire-FirstCall/ -- Patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R) ([risperidone] Long ...

Long-acting risperidone is a suspension administered by intramuscular injection in the upper-outer gluteal area. It consists of risperidone impregnated in microspheres composed of a biodegradable, ...

Uzedy administered once every 2 months is not recommended for the maintenance treatment of bipolar I disorder. The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release ...

Lupin has received approval from the Food and Drug Administration for risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial and 50 mg per vial, single-dose vials.

TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a long-acting subcutaneous risperidone injection for the treatment of schizophrenia in adults.

FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I ...

Luye Pharma Group Ltd. won marketing approval in China for its risperidone microspheres for injection to treat schizophrenia, which the company said is the first formulation developed by a Chinese ...

Long-acting risperidone injection is generally well tolerated and has an adverse-effect profile similar to that of oral risperidone. In the Kane et al. [33] trial, similar proportions of individuals ...